key: cord-1027054-h5pg4997 authors: Mohammad, Taj; Shamsi, Anas; Anwar, Saleha; Hussain, Afzal; Rehman, Md. Tabish; AlAjmi, Mohamed F.; Islam, Asimul; Hassan, Md. Imtaiyaz title: Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy date: 2020-07-24 journal: Virus Res DOI: 10.1016/j.virusres.2020.198102 sha: ac4bdac70ca6aaed53189096c2e5ebe1dc4f5189 doc_id: 1027054 cord_uid: h5pg4997 Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by a newly emerged highly pathogenic virus called novel severe acute respiratory syndrome coronavirus (SARS-CoV-2). Targeting the main protease (M(pro), 3CL(pro)) of SARS-CoV-2 is a justified approach for drug development because this enzyme plays a significant role in the viral replication and transcription. The available crystal structures of SARS-CoV-2 M(pro) determined in the presence of different ligands and inhibitors-like compounds provide a platform for the quick development of selective inhibitors of SARS-CoV-2 M(pro). In this study, we utilized the structural information of co-crystallized SARS-CoV-2 M(pro) for the structure-guided drug discovery approach to finding high-affinity inhibitors from the PubChem database. The screened compounds were selected on the basis of their physicochemical properties, drug-likeliness, and strength of affinity to the SARS-CoV-2 M(pro). Finally, we have identified 6-Deaminosinefungin (PubChem ID: 10428963) and UNII-O9H5KY11SV (PubChem ID: 71481120) as potential inhibitors of SARS-CoV-2 M(pro) which may be further exploited in drug development to address SARS-CoV-2 pathogenesis. Both compounds are structural analogs of known antiviral compounds, having considerable protease inhibitory potential with improved pharmacological properties. All-atom molecular dynamics simulations suggested SARS-CoV-2 M(pro) in complex with these compounds is stable during the simulation period with minimal structural changes. This work provides enough evidence for further implementation of the identified compounds in the development of effective therapeutics of COVID-19. Coronavirus disease 2019 (COVID-19) emerged from China and globally affected a larger population through human-to-human transmission (Guan et al., 2020) . Due to the high reproduction rate of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and unavailability of effective drugs and vaccines, the number of reported cases and death are increasing day by day . The disease is now pandemic across the globe claiming the death of more than 0.6 million lives worldwide (https://www.worldometers.info/coronavirus/). SARS-CoV-2 is belonging to Nidovirus superfamily of Coronavirus, which is an enveloped, positive-sense, single-stranded RNA virus, and the seventh coronavirus having the potential to infect humans (Chary et al., 2020; Naqvi et al., 2020) . The genome of SARS-CoV-2 is 29.9 kb and shows a high similarity to the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) (Lu et al., 2015b) . The genome of SARS-CoV-2 is composed of 13-15 open reading frames (ORFs) flanked by the 5′-untranslated region (UTR) and 3′-UTR (Lu et al., 2020) . All the ORFs are arranged as main replicase assembly encoding 27 structural and non-structural proteins Minakshi et al., 2014) . Two-third of its RNA situated in the first ORF (ORF1ab) that encodes a 7096 amino acids long polyprotein. The viral genome of SARS-CoV-2 translates into four major structural proteins viz. envelope (E), membrane (M), spike (S), and nucleocapsid (N) proteins. All these proteins play a vital role in the viral assembly (Zhang and Holmes, 2020) . The spike protein (S) is important for coronavirus transmission, as it mediates receptor binding and membrane fusion of the virus to the host angiotensin-converting enzyme 2 (ACE2) (Lu et al., 2015a; Wang et al., 2016) , a cell receptor for SARS-CoV-2. The S1 domain of S protein helps in receptor binding as it recognizes and binds to the host receptor through the receptorbinding domain (RBD), and the subsequent conformational transition of the S2 domain take place to facilitate the fusion of cell membrane (He et al., 2004; Wong et al., 2004; Zhou et al., 2020) . Transmembrane protease, serine 2 (TMPRSS2) plays a key role in the fusion of virus and host cell by priming S protein. The RBD binds to receptor ACE2 of the host which provides entry of SARS-CoV-2 to the respiratory tract (Zhou et al., 2020) . The affinity with which S protein of SARS-CoV-2 to the ACE2 is more than 10 times higher than that of SARS-CoV. The increased affinity of human ACE2 for the viral protein facilitates its high contagious nature among the human population (Wrapp et al., 2020) . The uncontrolled situation, mass infection, and larger death along with the lack of effective therapeutic measures are emergent issues globally. Several strategies have been employed to address COVID-19 by using existing broad-spectrum antivirals, including anti-HIV drugs such as ritonavir and lopinavir (Sheahan et al., 2020) . Amongst the well-characterized drug targets of coronaviruses, main protease (M pro , also called 3CL pro ) is mostly considered as it is essential for processing the polyproteins that are translated from the viral RNA (Anand et al., 2003) . M pro cuts polyproteins translated from viral RNA to produce functional viral proteins. This enzyme is primarily involved in the regulation of replication and transcription of virions, thus targeted to design and develop effective therapeutic molecules for COVID19. Computational methods can serve as a great asset in the present time due to their ability to work at a rapid and helping to find potential inhibitors for drug targets of SARS-CoV-2 (Shamsi et al., 2020) . Structure-based drug design and discovery are used to find effective molecules with high affinity and target specificity . The identification of new leads with high specificity is achieved by virtual high-throughput screening (vHTS) . This method identifies best drug-like candidates from a large chemical library based on the binding of ligands to target proteins with high affinity (Naqvi et al., 2018) . Prompt development of effective drugs for COVID-19 therapy is a difficult task as the conventional drug development process usually takes a long time and cost in billions. The repurposing of approved drugs offers an alternate approach to rapidly identify potential leads for the quick development of effective and safe drugs. In this study, we have extensively analyzed the available crystal structures of SARS-CoV-2 M pro co-crystallized with different compounds and employed to structure-guided rational drug design approach to find potential inhibitors with improved pharmacological properties (Dai et al., 2020; . First, molecular docking-based virtual screening of 121 reported compounds (co-crystallized with SARS-CoV-2 M pro ) was carried out to search high-affinity binding molecules for SARS-CoV-2 M pro which were served as scaffolds to screen the PubChem database with >90% structural similarity. Then, we reperformed molecular docking-based virtual screening of the PubChem compounds and estimated their binding affinities with SARS-CoV-2 M pro . Finally, J o u r n a l P r e -p r o o f after the interaction analysis and biological properties, we have identified two compounds for molecular dynamics (MD) simulations. A systematic approach based on structure-based drug designing was used in this study as described in Figure 1 . We have identified two compounds, 6-Deaminosinefungin (PubChem ID: 10428963) and UNII-O9H5KY11SV (PubChem ID: 71481120) as high-affinity inhibitors of SARS-CoV-2 M pro . The workflow demonstrates the process of virtual high-throughput screening used in this study. RO5, Lipinski's rule of five; ADMET, Absorption, Distribution, Metabolism, Excretion, and Toxicity. This study was performed on the DELL ® Workstation running on Ubuntu version 18.04.4 LTS. Computational tools, such as MGL Tools (Jacob et al., 2012) , AutoDock Vina (Trott and Olson, 2010) , and Discovery Studio visualizer (Biovia, 2015) were used for structure-guided virtual high throughput screening. A total of 158 SARS-CoV-2 M pro structures were retrieved from the PDB. Most of them were in complex with different inhibitors. We found a total of 121 unique ligands co-crystallized with SARS-CoV-2 M pro were extensively analyzed to get protocol for docking has been described in our previous communication (Shamsi et al., 2020) . Values of inhibition constant (pKi), the negative decimal logarithm of inhibition constants were calculated from the ∆G, generated from the docking study using the following formula- where ∆G, binding affinity (kcal/mol); R (gas constant), 1.98 cal*(mol*K) −1 ; T (temperature), 298.15 Kelvin; pred, predicted. Ligand efficiency (LE) is a commonly applied parameter for lead selection by comparing the values of average binding energy per atom (Hopkins et al., 2004) . The following formula was applied to calculate LE: where LE is the ligand efficiency (kcal mol -1 non-H atom -1 ), ∆G represents binding affinity (kcal mol -1 ) and N is the number of non-hydrogen atoms in the ligand. The docking result was marked off for high-affinity compounds. Subsequently, all possible docked conformers were splitted for their interaction analysis. All conformers were analyzed (1) (3) J o u r n a l P r e -p r o o f using PyMOL and Discovery Studio visualizer to explore their binding pattern and interactions with SARS-CoV-2 M pro . The interaction analysis was performed for only highly selective compounds that preferentially bind to the SARS-CoV-2 M pro substrate-binding pocket. To investigate the biological properties of the selected compounds, we have predicted their possible biological functions through the PASS webserver (Lagunin et al., 2000) . The PASS analysis allows for exploring the effects and properties of chemical compounds on the basis of their molecular formula. It uses multilevel neighbors of atoms (MNA) descriptors, suggesting the biological activity of a compound is the function of its chemical structure. It defines the prediction of biological properties of a compound based on the ratio of probability to be active (Pa) and probability to be inactive (Pi). Higher the Pa value for a prediction means the compound is having more probability to be active under that particular activity or biological property. Here, we selected only those compounds showing antiviral properties and protease inhibitory potential and subsequently discussed their analog properties with parent compounds. MD simulations were performed on three systems, one, the apo-SARS-CoV-2 M pro and the other two with the selected ligands, 10428963 and 71481120 for 50 ns at the molecular mechanics level using GROMOS 54A7 force-field in GROMACS 5.1.2 at 300 K. Compounds 10428963 and 71481120 were extracted out from the docked complexes, subsequently, their topology and force-field parameters were produced through the PRODRG webserver and then combined into the M pro topology to make the Gromacs complexed systems. All three systems were soaked in the Simple Point Charge (spc216) model for solvation and energy minimized using steepest descent approach under 1500 steps. Final MD run was performed for 50,000ps (50ns) for all three systems and the generated trajectories were analyzed using the inbuilt tools of GROMACS as described in our preceding communications Naqvi et al., 2018) . To study the conformational sampling and atomic motions of M pro and its docked complexes, principal component (PC) and free energy landscape (FEL) analyses were performed using the J o u r n a l P r e -p r o o f essential dynamics approach employing the calculation of the covariance matrix (Altis et al., 2008) . The covariance matrix was calculated while using the following formula: where xi/xj is the coordinate of the i th /j th atom of the systems, and < -> in the ensemble average. The FELs of a protein can be attained using a conformational sampling approach that allows exploring the protein conformations near the native state (Papaleo et al., 2009) . FELs were generated to investigate the stability and native states of SARS-CoV-2 M pro , before and after compounds binding. The FELs were generated as: where KB is the Boltzmann constant, T is the temperature of simulation, and P(X) is the probability distribution of the system along with the PCs. Out of 158 PDB entries of SARS-CoV-2 M pro , a total of 121 unique co-crystallized compounds were selected ( Table S1 ). Redocking of these compounds resulted in the identification of many hits as high-affinity binding ligands of SARS-CoV-2 M pro ( Table 1) . These compounds are showing considerable binding affinities to the SARS-CoV-2 M pro . Here, we have selected the top 10 hits with their binding affinities within the range of -8.3 kcal/mol to -7.5 kcal/mol ( Table 1) . A total of 10,433 PubChem compounds carrying at least 90% structure similarity with the top 10 hits were identified and screened for their drug-likeliness. After filtration based on physicochemical, ADMET, and other druglike properties, we got a set of 4,802 compounds satisfying the threshold of the applied filters of drug-likeness and RO5. These compounds were further screened out based on their affinities with SARS-CoV-2 M pro using molecular docking-based virtual screening and selected the top five compounds. These compounds show significant binding affinities toward SARS-CoV-2 M pro (-8.1 kcal/mol to -8.7 kcal/mol, Table 2 ). The docking analysis suggested that the identified compounds have improved druglike properties compared to their parent compounds reported in the structures of co-crystallized SARS-CoV-2 M pro . To explore the specific interaction of these five compounds, detailed interaction analysis of their possible docked conformers (9 for each compound) was carried out to find their preferential interaction with the SARS-CoV-2 M pro -binding pocket. We identified that all the selected compounds are showing many specific polar interactions with a set of critical residues, Thr25, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His163, his164, Glu166, Gln189 of SARS-CoV-2 M pro . All these compounds are mimicking the same binding pattern and sharing common interactions as co-crystallized SARS-CoV-2 M pro inhibitor K36 ( Figure 2 ). (originally Cys3408) acts as a nucleophile, and responsible for protease activity is participating in direct interaction with the identified compounds . Specific interactions and binding properties of these compounds make them potential leads to develop inhibitors of SARS-CoV-2 M pro . To explore the possible biological activities and antiviral potential of selected ligands, the PASS server prediction was carried. The analysis suggested that the selected compounds are J o u r n a l P r e -p r o o f having similar classes of biological activities. We identified two compounds, 10428963 and 71481120 which show antiviral activity through the protease inhibitory potential, with Pa ranging from 0,413 to 0,914 when Pa > Pi. The biological activities of the identified compounds with higher Pa value along with their ADMET properties are shown in Table 3 . where Cys145 is the active site of SARS-CoV-2 M pro , acts as a nucleophile, and responsible for the protease activity . Binding of any compound to these residues will hinder the substrate accessibility and thus inhibition of protease activity of SARS-CoV-2 M pro similar to the alpha-ketoamide/N3-ILP inhibitors reported . All these properties of 10428963 and 71481120 make them potential leads to develop SARS-CoV-2 M pro inhibitors that can be used in the development of safe and effective COVID-19 therapy. Three systems, SARS-CoV-2 M pro -apo, M pro -10428963, and M pro -71481120 complexes were subjected to MD simulation for 50 ns. Different systematic and structural properties of all three systems were explored to ascertain their stability and dynamics under the solvent condition during the simulation time. Binding of any small compound can make large changes to a protein structure. Root-mean- However, initially up to 10 ns, the M pro in presence of 71481120 was found with an increased Rg which suggesting initial adjustment of M pro binding pocket occupied with the ligand. Here, no structural shift was observed in M pro in the presence of the compounds where the Rg is attaining a stable equilibrium, suggests stability of protein-ligand complexes during the entire simulation ( Figure 4C) . The solvent-accessible surface area is calculated as an interface surrounded by a solvent (Ausaf Ali et al., 2014; Rodier et al., 2005) . This solvent behaves differently with varying conditions and thus a useful parameter to study the conformational dynamics of a protein in The dynamics of a protein structure can be illustrated through their phase space performance. We did PCA to study the conformational sampling of M pro in the free state as well as in complexed states with 10428963 and 71481120 via studying their collective motions while using the essential dynamics approach (Amadei et al., 1993) . The PCA analysis allows us to explore the dynamic motion and flexibility of a protein structure in conformational space. The conformational sampling of M pro and its docked complexes in the essential subspace is illustrated in Figure 6A . This projection shows the structural conformations of M pro along with the eigenvector (EV)-1 and EV-2 projected by C α atoms. Here, we observed that the M pro -10428963 and M pro -71481120 complex occupied the same conformational subspace as M pro in the free state. An increased dynamic was observed at EV1 in the case of the complexes, but no overall shift of the M pro in complexed with 10428963 and 71481120 was observed at both EVs ( Figure 6B ). Both complexes are overlapping the stable clusters with phase space of M pro -apo in the free state. PCA analysis including the RMSF indicates that M pro and its complexes are pretty stable during the entire simulation. J o u r n a l P r e -p r o o f In this study, we extensively analyzed the available SARS-CoV-2 M pro structures, cocrystallized with different molecules and inhibitor-like compounds investigate their binding pattern and mechanism of inhibition. We utilized the structural information of co-crystallized M pro structures to find high-affinity SARS-CoV-2 M pro inhibitors from the PubChem database. Construction of the free energy landscape of biomolecules via dihedral angle principal component analysis Essential dynamics of proteins Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states Discovery studio modeling environment COVID-19: Therapeutics and their toxicities Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Clinical characteristics of coronavirus disease 2019 in China Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine Ligand efficiency: a useful metric for lead selection. Drug discovery today 9 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Hydrogen Bonds in Proteins: Role and Strength Accessible high-throughput virtual screening molecular docking software for students and educators Inhibition of SARS-CoV 3CL protease by flavonoids Identification of α-Mangostin as a Potential Inhibitor of Microtubule Affinity Regulating Kinase 4 PASS: prediction of activity spectra for biologically active substances Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2 Bat-to-human: spike features determining 'host jump'of coronaviruses SARS-CoV, MERS-CoV, and beyond Complete genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) from the first imported MERS-CoV case in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding The SARS Coronavirus 3a protein binds calcium in its cytoplasmic domain Identification of high-affinity inhibitors of pyruvate dehydrogenase kinase-3: Towards therapeutic management of cancer Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4) Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structurefunction relationships Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression Binding studies and biological evaluation of beta-carotene as a potential inhibitor of human calcium/calmodulin-dependent protein kinase IV Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case Syntheses of 6-Deaminosinefungin and (S)-6-Methyl-6-deaminosinefungin Hydration of protein-protein interfaces Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: Towards therapeutic management of Alzheimer's disease MERS-CoV spike protein: Targets for vaccines and therapeutics A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors A Genomic Perspective on the Origin and Emergence of SARS-CoV-2 A pneumonia outbreak associated with a new coronavirus of probable bat origin Declaration of Competing Interest: The authors declare that they have no conflict of interest.